Are You Embarking on a GLP-1 Journey? We Want to Hear From You.

The New York Times is interested in hearing the experiences of individuals who have used GLP-1 drugs such as Ozempic and Wegovy to address health issues like chronic illness, obesity, or mental health. They are particularly keen to hear from groups of people, such as friends or families, who have taken these medications collectively. Respondents can share their stories, and all information provided will remain confidential. The Times will only use contact information to follow up with respondents and will not share it externally.